Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
An announcement from Cencora ( (COR) ) is now available.
On May 15, 2025, Cencora, Inc. entered into an Underwriting Agreement with several financial institutions for the issuance and sale of €1 billion in senior notes, split between €500 million due in 2028 and €500 million due in 2032. These notes are senior unsecured obligations, and the company expects to complete the sale by May 22, 2025, with net proceeds of approximately €994 million intended for general corporate purposes. The underwriters involved have previously provided various financial services to Cencora and may continue to do so in the future.
The most recent analyst rating on (COR) stock is a Hold with a $245.00 price target. To see the full list of analyst forecasts on Cencora stock, see the COR Stock Forecast page.
Spark’s Take on COR Stock
According to Spark, TipRanks’ AI Analyst, COR is a Outperform.
Cencora is performing strongly with robust revenue growth, operational efficiency, and effective cost management. The high leverage is a notable risk, but the company’s strategic focus on expanding its specialty medication offerings and raising guidance reflects confidence in future performance. The technical analysis and valuation suggest caution, as the stock may be experiencing consolidation, and the high P/E ratio points to potential overvaluation.
To see Spark’s full report on COR stock, click here.
More about Cencora
Average Trading Volume: 1,885,305
Technical Sentiment Signal: Buy
Current Market Cap: $56.25B
See more insights into COR stock on TipRanks’ Stock Analysis page.